Skip to main content
Facebook
Tweet
Welcome
Search form
Search
Menu
Home
About Us
What is ALS?
Mission Statement
Work for EUpALS
Governance
Board of Directors
Patients and Carers Expert Board
Scientific Expert Board
Member Associations
Overview Members
Miquel Valls
APELA
Fundacion Francisco Luzon
MND Iceland
Stichting ALS Nederland
Arsla
Stiftelsen ALS Norsk StØttegruppe
ALS Liga
Aisla Onlus
ALS patiëntenvereniging
The ALS Association of Republic Srpska, Bosnia and Herzegovina
MND Association England, Wales and Northern Ireland
Motus Vita
ALS-tutkimuksen tuki ry
Društvo Distrofikov Slovenije / Muscular Dystrophy Association of Slovenia
EAMDA - European Alliance of Neuromuscular Disorders Association
ALS-MNH Derneği / ALS/MND Association Turkey
Ulla-Carin Lindquist Stiftelse för ALS-forskning
Irish Motor Neurone Disease Association (IMNDA)
Muskelsvindfonden
Research Motor Neurone (RMN)
Foundation LIVE NOW
ALS Association Switzerland
Activities
Membership
Membership request
Partners
Academic Partners
Industry partners
Real4reg
News
Newsletters
ALS Trials
ALS Research news
Donate
Contact
You are here
Home
» Januari 10, 2024 - Ferrer Phase 3 ADORE trial with FAB122 (oral Edaravone) does not meet primary and secondary endpoints
Januari 10, 2024 - Ferrer Phase 3 ADORE trial with FAB122 (oral Edaravone) does not meet primary and secondary endpoints
Submitted by
wim@als.be
on Wed, 01/10/2024 - 10:55
files:
ferrer_phase_3_adore_trial_with_fnp122_oral_edaravone_does_not_meet_primary_and_secondary_endpoints.pdf
